What is this study trying to find out about ocular tumors?

This study is comparing two optical coherence tomography devices to see how well they image ocular tumors. Researchers want to understand which device provides better image quality and field of view to help monitor these tumors. The study is led by Memorial Sloan Kettering Cancer Center and aims to improve eye tumor detection and monitoring methods.

Who may be eligible for this ocular tumor clinical trial?

Adults aged 18 or older with at least one eye affected by an intraocular or ocular surface tumor may be eligible. Participants must have a natural or intraocular lens, pupils that can dilate at least 3 mm, and be able to sit still and focus during imaging. Please review eligibility criteria for more details.

Is there any cost to participate in this ocular tumor clinical trial?

Study-related care, including the imaging procedures and all trial visits, is provided at no cost. Personal travel expenses may vary and are not guaranteed to be covered. Participants should consider these factors when planning involvement.

Actively Recruiting

Phase Not Applicable

Age: 18Years +

All Genders

ID07449195

Ocular Imaging for Monitoring of Ocular Tumor Disease

Led by Memorial Sloan Kettering Cancer Center · Updated on 2026-05-13

Participants Needed

Research Sites

N/A

Total Duration

AI-Summary

What this Trial Is About

Researchers are comparing two devices used for optical coherence tomography OCT, a noninvasive scanning method that uses reflected light to create images of the back of the eye. This technique helps doctors detect and monitor different types of ocular tumors. The study is led by Memorial Sloan Kettering Cancer Center and focuses on people with at least one eye affected by an intraocular or ocular surface tumor. The study evaluates the Intalight Dream OCT, a next-generation swept-source device with faster imaging speed and higher sensitivity, against the Heidelberg Spectralis OCT, which is the current standard of care for optical imaging. Participants will undergo imaging using both devices to compare image quality and field of view over a period of up to one year. Participants will be assessed for image quality and field of view during the study. To be part of the study, they must have pupils that can dilate adequately and be able to sit still and fixate on the imaging target during the procedure, which takes approximately 2 minutes. The study enrollment begins in February 2026 and continues until February 2028, with ongoing monitoring of imaging results throughout this period.

CONDITIONS

Brief Title

A Study Comparing Two Optical Coherence Tomography Devices in People With Ocular Tumors

Who Can Participate

Age: 18Years +

All Genders

Eligibility Criteria

You may qualify if you...

Age 18 years or older
At least one eye with an intraocular or ocular surface tumor
Presence of a natural crystalline lens or intraocular lens
Pupils that can dilate at least 3 millimeters in the study eye(s)
No opaque natural crystalline lenses or ocular disease preventing retinal imaging
Ability to fixate on the imaging target
Ability to sit still for about 2 minutes during imaging

You will not qualify if you...

Does not meet all of the above inclusion criteria

Research Team

Jasmine Francis, MD

David Abramson, MD

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here